ABSTRACT
@#[Abstract] Glioblastoma multiforme（GBM）is a malignant tumor of central nervous system with high incidence, aggressive and poor prognosis. Since temozolomide was approved by FDAin 2005, there is no new curative strategy with obvious improvement in therapeutic effect. With the developments in molecular biology, tumor immunology and immunotherapy technology, the discovery of new molecular targets, breakthrough in central immunization exemption theory, and advance in gene transduction and cell technology, GBM immunotherapy ushered in a new breakthrough in immunotherapy. Cellular immunotherapy, presented by chimeric antigen receptor-modified T cell (CAR-T) therapy, has exhibiteditsprominentapplicationprospectinGBMinvitro experimentstargetingEGFRvIII, IL-13Rα2, HER2, erythropoietin-producing hepatocellular carcinomaA2 (EphA2), animal models and early clinical trials. However, the GBM molecular heterogeneity, immunosuppressive microenvironment and blood-brain barrier have presented challenge for CAR-T going into the first-line clinical treatment. Researchers are now exploring key antigens of oncogenic phenotype, designing optimal combination of target antigens to prevent the immune escape, improving CAR-T passing through blood-brain barrier and invading tumor tissue, finding the best route for cell deliver, and optimizing evaluation system for central nervous system (CNS) immunotherapy. It is believed that the breakthrough of CAR-T cell immunotherapy will finally help GBM patients pursuing a beautiful life.